Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-19520
Steffen, R; Sack, D A; Riopel, L; Jiang, Z D; Stürchler, M; Ericsson, C D; Lowe, B; Waiyaki, P; White, M; DuPont, H L (2003). Therapy of travelers' diarrhea with rifaximin on various continents. American Journal of Gastroenterology, 98(5):1073-1078.
- Registered users only
View at publisher
OBJECTIVE: Our aim was to compare the efficacy and safety of rifaximin, a virtually nonabsorbed antibiotic, 600 and 1200 mg per day, with placebo in patients with travelers' diarrhea. METHODS: This was a multicenter, 1:1:1 randomized, parallel-group, double-blind study, conducted in Antigua, Guatemala; Guadalajara and Morelia, Mexico; and the coast of Kenya north and south of Mombasa. Adult patients with acute travelers' diarrhea were recruited; exclusion criteria included primarily medication that could influence the outcome. Subjects were treated for 3 days, three times daily; follow-up lasted 5 days. For each 24-h period, the subjects completed a diary card. Pre- and posttreatment stool, blood, and urine samples were assessed. RESULTS: Among the 380 volunteers, median time to the last unformed stool was 32.5 and 32.9 h in both rifaximin groups, compared with 60.0 h with placebo (p = 0.0001). Also, secondary clinical outcome measures were favorably influenced by the active agent. No relevant side effects were reported. CONCLUSION: Rifaximin is efficacious and safe for treatment of travelers' diarrhea at daily doses of 600 mg or higher.
2 downloads since deposited on 30 Jun 2009
0 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||30 Jun 2009 14:46|
|Last Modified:||05 Apr 2016 13:17|
|Publisher:||Nature Publishing Group|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page